AbCellera Biologics Inc. (NASDAQ: ABCL), the Vancouver-based biotechnology company developing antibody medicines, will present additional Phase 1/2 clinical findings for ABCL635, its investigational long-acting neurokinin 3 receptor antagonist, at The Menopause Society’s 2026 Annual Meeting in San Diego on October 22. The presentation will include newly disclosed safety data from the Phase 1 multiple ascending dose study and additional patient-reported outcomes from the Phase 2 trial in postmenopausal women experiencing moderate-to-severe vasomotor symptoms, commonly known as hot flashes.
The October 8 announcement follows AbCellera’s August 10 disclosure of positive Phase 2 results showing that a single 600 mg subcutaneous dose of ABCL635 reduced moderate-to-severe hot flash frequency by an average of 83% after four weeks, compared with 33% among placebo recipients. The study enrolled 92 women and met its primary efficacy endpoints for symptom frequency and severity, establishing an initial placebo-controlled efficacy signal. However, the forthcoming conference presentation has not yet taken place, and the new multiple-dose safety findings and additional patient-reported outcome results have not been publicly quantified in the announcement.
The development places AbCellera in a growing market for non-hormonal menopause treatments, where neurokinin receptor antagonists have emerged as an alternative for women seeking relief from disruptive hot flashes and night sweats. Unlike currently approved oral therapies targeting the neurokinin signalling pathway, ABCL635 is being developed as a monoclonal antibody administered by subcutaneous injection, potentially allowing less frequent dosing. Whether this delivery approach produces a durable clinical advantage will depend on longer-term efficacy, repeat-dose safety, tolerability and the practicality of administering an injectable treatment for a chronic symptom condition.
The upcoming presentation therefore represents an opportunity to evaluate evidence beyond the company’s initial four-week efficacy announcement. Pharmacokinetic and pharmacodynamic information may help establish how long ABCL635 remains active, while additional safety findings could provide an early indication of whether repeat administration introduces new concerns. These data will be important in determining the strength of the clinical development rationale, but they should not be interpreted as the results of a completed pivotal trial or as evidence that the investigational medicine is approaching regulatory approval.
What did the 92-patient ABCL635 Phase 2 trial establish about hot flash frequency and severity?
The Phase 2 component of study NCT07118891 was a multicentre, randomised, double-blind, placebo-controlled trial involving 92 postmenopausal women aged approximately 40 to 75 years. Participants experienced an average of about 10 moderate-to-severe vasomotor symptoms daily at baseline and were assigned equally to receive either a single 600 mg subcutaneous dose of ABCL635 or placebo. The primary efficacy analyses evaluated changes in symptom frequency and severity over four weeks using repeated-measures statistical methods.
AbCellera reported that the treatment group experienced a mean reduction of 8.8 moderate-to-severe hot flashes per day at Week 4, compared with a reduction of 3.5 events among placebo recipients. The resulting placebo-adjusted difference was 5.3 fewer daily episodes, with a reported p-value below 0.001. The company also reported statistically significant differences beginning at Week 1, indicating that separation from placebo emerged relatively early during the observation period.
The severity results supported the frequency findings. ABCL635 produced a mean reduction of 1.4 points in the study’s symptom severity score at Week 4, compared with 0.3 points for placebo, resulting in a placebo-adjusted difference of 1.1 points. Expressed as percentage changes from baseline, severity decreased by an average of 58% in the active-treatment group and 12% in the placebo group.
These findings provide encouraging controlled evidence of short-term clinical activity, particularly because both primary efficacy measures favoured the investigational antibody. Nevertheless, a statistically significant result at four weeks does not establish the optimal dosing interval, the durability of symptom control or the safety of treatment administered repeatedly over months or years. Those considerations are especially important for a medicine intended to treat symptoms that may persist throughout a substantial portion of the menopausal transition.
Why could the new patient-reported outcome results provide important evidence beyond hot flash counts?
The October 22 presentation will include additional patient-reported outcomes from the Phase 2 programme, expanding the evidence available beyond the frequency and severity measurements disclosed in August. These outcomes are relevant because vasomotor symptoms can disrupt sleep, concentration, work activities and daily functioning even when individual episodes are relatively brief. A treatment that reduces symptom counts but produces little improvement in everyday wellbeing may deliver less practical value than its primary efficacy results initially suggest.
AbCellera’s earlier clinical presentation already reported improvement in sleep disturbance using the Patient-Reported Outcomes Measurement Information System Sleep Disturbance Short Form. At Week 4, the company reported a placebo-adjusted treatment difference of minus 5.5 points in the sleep disturbance T-score. Improvements were described across measures addressing difficulty falling asleep, difficulty remaining asleep, sleep quality, restlessness and feeling refreshed.
Patient Global Impression of Change results provided another perspective on the reported treatment response. At Week 4, 84% of participants receiving ABCL635 rated their symptoms as moderately or much better, compared with 27% of placebo recipients. These findings suggest that the improvements detected through symptom diaries were accompanied by perceived benefits among many treated participants.
However, patient-reported outcomes require careful interpretation because they reflect participants’ subjective experience and can be influenced by expectations, baseline symptom burden and the questionnaires used. The double-blind, placebo-controlled design strengthens the credibility of the observed differences, but a larger confirmatory study would still be necessary to establish reproducibility. The forthcoming results could help clarify the consistency of the response across additional patient-reported measures without replacing the need for longer-term controlled evidence.
What could the Phase 1 multiple ascending dose safety results reveal about repeated ABCL635 treatment?
The new Phase 1 safety findings may be among the most consequential elements of the forthcoming presentation because the intended clinical benefit depends on maintaining treatment over time. The earlier Phase 2 disclosure primarily described tolerability during the first four weeks following a single injection. A multiple ascending dose study can provide additional information about systemic exposure, tolerability following repeated administration and whether adverse events become more frequent or pronounced at different doses.
In the previously disclosed Phase 2 dataset, 31 of the 46 ABCL635 recipients, representing 67.4%, experienced at least one adverse event, compared with 24 of 46 placebo recipients, or 52.2%. The company reported no serious adverse events or Grade 3 or higher adverse events in the active-treatment group during the four-week period. The placebo group recorded one serious adverse event and two Grade 3 adverse events.
Headache was reported in 28.2% of ABCL635 recipients compared with 13.0% of placebo participants, while fatigue occurred in 13.0% and 6.5%, respectively. Injection-site reactions were reported in 8.7% of the treatment group and 6.5% of placebo recipients. These differences are relevant to tolerability, even though the disclosed trial did not identify serious or severe adverse events among participants receiving the investigational antibody.
Liver safety will receive particular attention because of the experience with other medicines targeting neurokinin receptors. AbCellera previously reported one mild transaminase elevation involving a treated participant, with aspartate aminotransferase reaching 92 IU/L and alanine aminotransferase reaching 66 IU/L before the abnormality resolved within one week. The company reported no broader liver safety signal in the available four-week dataset, but this limited observation cannot establish an absence of hepatotoxicity during prolonged treatment.
The additional Phase 1 findings may help researchers understand whether repeated exposure produces changes in laboratory measurements or tolerability that were not apparent after a single dose. Immune responses to the antibody, accumulation with repeat dosing and the relationship between drug exposure and adverse events will also be relevant considerations for continued development. The October announcement does not disclose numerical results from the multiple ascending dose assessment, so conclusions about its longer-term safety must await the presentation.
How does ABCL635’s antibody mechanism differ from approved oral NK3 receptor antagonists?
ABCL635 is designed to selectively block the neurokinin 3 receptor, a G protein-coupled receptor involved in regulating body temperature. The receptor is expressed on hypothalamic neurons commonly described as KNDy neurons, referring to their involvement with kisspeptin, neurokinin B and dynorphin signalling. Changes in estrogen signalling during menopause can alter the activity of this neuronal network, contributing to the thermoregulatory instability associated with hot flashes.
Targeting the neurokinin pathway is an established therapeutic strategy, but ABCL635 approaches the receptor using a monoclonal antibody rather than a conventional small-molecule medicine. Antibody-based products can have pharmacokinetic properties different from orally administered small molecules, potentially allowing longer intervals between doses. Whether those characteristics provide a meaningful clinical advantage depends on the actual exposure profile, receptor engagement, safety and duration of symptom reduction.
The programme also represents an important technical milestone for AbCellera’s antibody discovery platform. G protein-coupled receptors are complex membrane proteins that can present challenges for antibody discovery and development because therapeutically relevant binding sites may be difficult to access. ABCL635 is the company’s first programme generated through its GPCR and ion channel platform to reach clinical testing, giving the company an opportunity to evaluate the platform’s ability to produce a biologically active antibody against this target class.
However, the antibody’s mechanism does not independently establish superiority over oral therapies. Long duration of action can be advantageous when treatment provides sustained benefit, but it may also complicate management if an adverse reaction occurs and the medicine cannot be rapidly eliminated. Future clinical studies will need to establish how the pharmacological properties translate into a practical benefit-risk profile.
Can ABCL635 compete with Veozah and Lynkuet in the expanding non-hormonal menopause market?
The competitive environment has evolved with the introduction of medicines targeting neurokinin signalling. Astellas Pharma’s Veozah (fezolinetant) received United States Food and Drug Administration approval in May 2023 for moderate-to-severe vasomotor symptoms due to menopause. Bayer’s Lynkuet (elinzanetant), which targets neurokinin 1 and neurokinin 3 receptors, received United States approval in October 2025.
Both medicines offer non-hormonal oral treatment options, establishing a clinically relevant alternative for patients and prescribers considering different approaches to menopausal symptom management. ABCL635 could eventually differentiate itself through a longer-acting injectable formulation, particularly if patients prefer less frequent administration. However, its comparative value will depend on safety, clinical effectiveness, treatment duration, administration preferences and eventual cost.
Safety considerations are particularly relevant because Veozah carries a boxed warning concerning the risk of serious liver injury. The FDA strengthened the product’s liver safety requirements after post-marketing reports, including recommendations for liver-function testing before treatment and during defined follow-up intervals. This established safety experience makes liver-related findings an important part of evaluating newer neurokinin receptor antagonists.
AbCellera has suggested that ABCL635 could offer favourable tolerability characteristics, including potentially fewer liver and gastrointestinal concerns. The early Phase 2 findings provide limited support for further investigation, but they do not establish a superior safety profile against approved products. The trials involved different populations, treatment durations, formulations and monitoring procedures, preventing reliable comparisons based solely on reported percentages.
A direct comparative trial would provide stronger evidence if the company ultimately seeks to demonstrate superiority over existing treatments. Alternatively, appropriately designed placebo-controlled Phase 3 studies could establish the medicine’s efficacy and safety for regulatory purposes without requiring a superiority claim. Commercial differentiation would then depend on the totality of the evidence and the practical value of its proposed dosing schedule.
Why will dose durability and pharmacokinetics shape the next stage of ABCL635 development?
The available Phase 2 findings demonstrate symptom reduction for four weeks after a single 600 mg injection, but the appropriate long-term dosing regimen has not been definitively established. AbCellera has described the therapy as a potential long-acting treatment, with once-monthly administration examined in its clinical programme. Confirming whether that interval consistently maintains adequate symptom control will be important before advancing into larger studies.
Pharmacokinetic measurements could help determine how ABCL635 concentrations change after administration and whether repeated injections produce predictable exposure. Pharmacodynamic data may clarify the relationship between drug exposure, biological target engagement and clinical response. Together, these assessments can inform dose selection and determine whether higher or lower dosing levels offer an appropriate balance of clinical activity and tolerability.
AbCellera previously identified completion of 12-week follow-up as an important development activity supporting dose selection. The company’s August presentation also indicated plans for regulatory discussions concerning late-stage development. However, the October 8 announcement does not confirm that the FDA has approved a particular Phase 3 protocol, that pivotal enrolment has begun or that a definitive regulatory submission timeline has been established.
The design of future trials will be important because menopause-related vasomotor symptoms frequently persist beyond the short observation periods used in early clinical studies. Confirmatory programmes may need to evaluate sustained symptom frequency and severity reductions, patient-reported quality-of-life outcomes and safety during repeated treatment. They will also need sufficient enrolment to characterise adverse events that are difficult to detect in a 92-participant study.
How does AbCellera’s financial position support its expanding internal drug pipeline?
AbCellera’s shift towards developing internally originated antibody medicines introduces different capital requirements from its historical partnership-focused discovery model. Advancing ABCL635 through larger clinical trials could require substantial expenditure on manufacturing, clinical operations, regulatory activities and follow-up studies. The company’s ability to fund this progression is therefore an important commercial consideration alongside the clinical evidence.
For the second quarter of 2026, AbCellera reported revenue of $4.1 million, compared with $17.1 million during the corresponding period in 2025. Its net loss increased to $55.4 million from $34.7 million, while research and development expenditure reached $46.0 million. These figures reflect a business investing heavily in development activities while revenue from research and licensing arrangements remains variable.
The company reported more than $565 million in total cash balances and marketable securities at June 30, 2026. It also identified approximately $110 million in available non-dilutive government funding, bringing its reported total available liquidity above $675 million. The government funding component should not be treated as unrestricted cash already held on the balance sheet, since availability may depend on applicable programme requirements.
Following the positive ABCL635 results, AbCellera priced an approximately $200 million gross public offering of common shares and pre-funded warrants in August. The offering included 17,435,897 common shares priced at $9.75 each and pre-funded warrants covering up to 3,076,926 additional shares. The company indicated that the proceeds were intended to support internal development programmes, including ABCL635, alongside working capital and general corporate requirements.
This financing activity provides additional context for management’s willingness to advance the programme, although the gross offering amount is not equivalent to net proceeds after transaction expenses. The issuance also increases the potential share count, making dilution relevant when assessing the financial consequences for existing shareholders. AbCellera’s development strategy will ultimately depend on how efficiently it converts its funding capacity into clinical evidence capable of supporting additional investment or partnerships.
What does AbCellera’s recent stock performance suggest about expectations for ABCL635?
AbCellera shares closed at $12.55 on the Nasdaq on October 9, 2026, increasing approximately 4.37% from the previous session’s closing price of $12.02. The stock traded between $11.93 and $12.79 during the session, reflecting a rebound after several days of weaker performance. Shares had closed at $13.91 on October 1, illustrating the volatility surrounding the company during the early part of the month.
The recent trading pattern suggests that investor expectations remain sensitive to clinical development milestones, although the October 9 recovery cannot be attributed exclusively to the forthcoming menopause conference presentation. ABCL635 had already attracted attention following its positive August Phase 2 results and subsequent financing announcement. Investors are now assessing whether the clinical programme can progress towards larger studies without encountering safety or development challenges that materially alter its prospects.
The company’s valuation also reflects a broader portfolio of antibody programmes and research partnerships, including agreements with Vertex Pharmaceuticals Incorporated and Jazz Pharmaceuticals plc. Those collaborations provide potential sources of research revenue and future contingent payments, but their economics differ from ownership of an internally developed medicine. The value ultimately attributable to ABCL635 will depend on future clinical evidence, development expenditure, commercial rights and any partnership strategy adopted by AbCellera.
Near-term market sentiment may respond to the detail of the October presentation, particularly if new safety findings provide greater clarity on repeat dosing. However, a conference presentation is not equivalent to regulatory approval or commercial validation, and the clinical implications should remain separate from short-term share-price movements. Sustained changes in the programme’s value will require evidence that its efficacy and tolerability remain convincing as patient exposure and follow-up increase.
What should clinicians and investors look for at The Menopause Society 2026 presentation?
AbCellera’s presentation is scheduled for Thursday, October 22, 2026, between 6:15 p.m. and 7:15 p.m. Pacific Daylight Time at the Hilton Bayfront in San Diego. The poster, identified as P-92, will address safety, pharmacokinetics, pharmacodynamics and preliminary efficacy from the combined Phase 1/2 clinical programme. The scheduled inclusion of new multiple-dose safety information and additional patient-reported outcomes creates an opportunity to evaluate aspects of ABCL635 that remain incompletely characterised.
For clinicians, the most informative disclosures will include detailed adverse-event information, liver laboratory findings, repeat-dose tolerability and the consistency of improvements in sleep and daily functioning. Pharmacokinetic and pharmacodynamic findings could help establish whether the observed duration of clinical response is compatible with a practical long-term administration schedule. Greater clarity on individual patient responses would also help distinguish consistent therapeutic benefit from variation across a relatively small study population.
The distinction between the new and previously disclosed evidence will be important. AbCellera has already reported statistically significant Week 4 reductions in hot flash frequency and severity, along with improvements in sleep and patient global impression of change. The October presentation must therefore add meaningful detail about treatment exposure, tolerability or clinical experience to materially strengthen the development case.
For investors, the next important milestone will be evidence supporting regulatory discussions and the design of an appropriately powered late-stage programme. The company has demonstrated a promising short-term clinical response with a novel antibody targeting NK3R, but it has not established long-term safety, durable efficacy or commercial competitiveness. Its ability to address those questions will determine whether ABCL635 can progress from an encouraging Phase 2 candidate towards a credible new non-hormonal treatment option for menopause-associated vasomotor symptoms.
